Rapport Therapeutics surges after seizure drug meets main goals in mid-stage trial

** Shares of drug developer Rapport Therapeutics RAPP.O more than double to $30 premarket

** RAPP's experimental oral drug, RAP-219, was tested in 30 patients in a mid-stage trial for adults with hard-to-treat focal seizures, where a brain device was implanted to track seizure activity

** Co says patients saw a median 77.8% drop in seizures, and 24% achieved seizure freedom after the eight-week treatment

** Rapport says it plans to meet U.S. regulators later this year and start two late-stage studies in the third quarter of 2026

** As of last close, RAPP stock down 19.5% YTD